Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A patient-led survey on information and communication needs of patients with metastatic breast cancer in Ireland and Northern Ireland (CTRIAL-IE 23-05).
Gaynor S, O'Meara Y, Mulvaney E, Keogh RJ, Weadick CS, Duane FJ, Mc Brien A, Greally H, O'Leary MJ, Teiserskyte I, Beristain I, Marron J, Mulroe E, Donachie V, Mc Loughlin S, O'Reilly S. Gaynor S, et al. Among authors: mulroe e. Breast. 2024 Nov 20;79:103837. doi: 10.1016/j.breast.2024.103837. Online ahead of print. Breast. 2024. PMID: 39591880
Optimising oncology drug expenditure in Ireland.
Kieran R, Hennessy M, Coakley K, O'Sullivan H, Cronin T, Lynch D, Mulroe E, Cooke K, Collins D, O'Reilly S. Kieran R, et al. Among authors: mulroe e. Ir J Med Sci. 2024 Aug;193(4):1735-1747. doi: 10.1007/s11845-024-03672-y. Epub 2024 Apr 3. Ir J Med Sci. 2024. PMID: 38568369 Free PMC article. Review.
Neoadjuvant trastuzumab deruxtecan (T-DXd) with response-directed definitive therapy in early stage HER2-positive breast cancer: a phase II study protocol (SHAMROCK study).
Dowling GP, Toomey S, Bredin P, Parker I, Mulroe E, Marron J, McLoughlin O, Teiserskiene A, Power C, O'Shea AM, Greally M, Morris PG, Duke D, Hill ADK, Hennessy BT. Dowling GP, et al. Among authors: mulroe e. BMC Cancer. 2024 Jan 17;24(1):91. doi: 10.1186/s12885-024-11851-4. BMC Cancer. 2024. PMID: 38233810 Free PMC article.
Health diplomacy in action: The cancer legacy of the Good Friday Agreement.
Lawler M, Sullivan R, Abou-Alfa GK, McCloskey K, Keatley D, Feighan J, Dahut W, Mulroe E, Ladner R, Genead M, Lowery M, Gulley JL, Scott CJ, Longley DB, Culhane A, Gallagher WM, Orr N, Chanock SJ, Gopal S. Lawler M, et al. Among authors: mulroe e. J Cancer Policy. 2023 Dec;38:100448. doi: 10.1016/j.jcpo.2023.100448. Epub 2023 Oct 14. J Cancer Policy. 2023. PMID: 37839622 Free article.
Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, phase 3 trial.
Reynolds JV, Preston SR, O'Neill B, Lowery MA, Baeksgaard L, Crosby T, Cunningham M, Cuffe S, Griffiths GO, Parker I, Risumlund SL, Roy R, Falk S, Hanna GB, Bartlett FR, Alvarez-Iglesias A, Achiam MP, Nilsson M, Piessen G, Ravi N, O'Toole D, Johnston C, McDermott RS, Turkington RC, Wahed S, Sothi S, Ford H, Wadley MS, Power D; Neo-AEGIS Investigators and Trial Group. Reynolds JV, et al. Lancet Gastroenterol Hepatol. 2023 Nov;8(11):1015-1027. doi: 10.1016/S2468-1253(23)00243-1. Epub 2023 Sep 18. Lancet Gastroenterol Hepatol. 2023. PMID: 37734399 Free PMC article. Clinical Trial.
Climate toxicity: An increasingly relevant clinical issue in Cancer Care.
Weadick CS, Keogh RJ, Carroll HK, Boldrin S, Mulroe E, Murphy L, Sheils B, Barry A, O'Reilly S. Weadick CS, et al. Among authors: mulroe e. J Cancer Policy. 2023 Mar;35:100410. doi: 10.1016/j.jcpo.2023.100410. Epub 2023 Feb 9. J Cancer Policy. 2023. PMID: 36773799 Free article.
The SARS-CoV-2 Pandemic and Cancer Trials Ireland: Impact, Resolution and Legacy.
O'Reilly S, Murphy V, Mulroe E, Tucker L, Carragher F, Marron J, Shannon AM, Rogan K, Connolly RM, Hennessy BT, McDermott RS. O'Reilly S, et al. Among authors: mulroe e. Cancers (Basel). 2022 Apr 30;14(9):2247. doi: 10.3390/cancers14092247. Cancers (Basel). 2022. PMID: 35565375 Free PMC article.
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer.
Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S, Coskinas X, Frydenberg M, Hague WE, Horvath LG, Joshua AM, Lawrence NJ, Marx G, McCaffrey J, McDermott R, McJannett M, North SA, Parnis F, Parulekar W, Pook DW, Reaume MN, Sandhu SK, Tan A, Tan TH, Thomson A, Tu E, Vera-Badillo F, Williams SG, Yip S, Zhang AY, Zielinski RR, Sweeney CJ; ENZAMET Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Davis ID, et al. N Engl J Med. 2019 Jul 11;381(2):121-131. doi: 10.1056/NEJMoa1903835. Epub 2019 Jun 2. N Engl J Med. 2019. PMID: 31157964 Clinical Trial.